This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALDR Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Alder Biopharmaceuticals Stock (NASDAQ:ALDR) Get ALDR alerts:Sign Up Key Stats Today's Range$18.88▼$18.8850-Day Range$18.88▼$18.8852-Week Range$8.39▼$19.12VolumeN/AAverage Volume5.12 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Read More Receive ALDR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALDR Stock News HeadlinesAlder Hey measles death: Liverpool's top health boss very worried spread of disease could spark health crisisJuly 17, 2025 | msn.comNew details released after child with measles dies at Alder HeyJuly 14, 2025 | msn.comPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.September 20 at 2:00 AM | Stansberry Research (Ad)Alder Hey's plea after child dies with measlesJuly 13, 2025 | msn.comChild with measles dies in Alder Hey as health officials fear outbreakJuly 13, 2025 | msn.comChild dies at Alder Hey after contracting measlesJuly 13, 2025 | bbc.comBMore children and young people at Alder Hey Children's Hospital waiting for mental health treatmentJuly 11, 2025 | msn.comAlder Hey Children's Hospital: how long patients waited for NHS treatment in MayJuly 10, 2025 | msn.comSee More Headlines ALDR Stock Analysis - Frequently Asked Questions How were Alder Biopharmaceuticals' earnings last quarter? Alder Biopharmaceuticals Inc (NASDAQ:ALDR) issued its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.01. What other stocks do shareholders of Alder Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alder Biopharmaceuticals investors own include Bristol Myers Squibb (BMY), (CPXX) (CPXX), NVIDIA (NVDA), Celldex Therapeutics (CLDX), Meta Platforms (META), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/07/2018Today9/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDR CIK1423824 Webwww.alderbio.com Phone425-205-2900FaxN/AEmployees202Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-226.13% Return on Assets-66.86% Debt Debt-to-Equity Ratio1.74 Current Ratio8.94 Quick Ratio8.94 Sales & Book Value Annual Sales$1.62 million Price / Sales977.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book11.73Miscellaneous Outstanding Shares83,840,000Free FloatN/AMarket Cap$1.58 billion OptionableOptionable Beta2.64 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ALDR) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alder Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alder Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
